Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Almirall ( (ES:ALM) ) just unveiled an announcement.
Almirall has identified an external error in the previously reported weighted average share price used to calculate the terms of its scrip dividend-related bonus share capital increase, correcting the reference price from €10.291 to €12.349 per share. Based on the revised price, the company has updated key parameters of the capital increase, including a maximum nominal amount of €396,526.44, up to 3,304,387 new shares, a ratio of 65 rights per new share, and a cash purchase price of €0.187, while keeping the previously announced timetable unchanged, thereby providing clarity and stability for shareholders participating in the dividend alternative.
The most recent analyst rating on (ES:ALM) stock is a Hold with a EUR14.00 price target. To see the full list of analyst forecasts on Almirall stock, see the ES:ALM Stock Forecast page.
More about Almirall
Almirall, S.A. is a Spanish pharmaceutical company focused on developing and marketing prescription medicines, with a particular emphasis on dermatology and related therapeutic areas. The company targets both European and international markets, providing treatments that address chronic conditions and specialist care needs in collaboration with healthcare professionals.
Average Trading Volume: 149,849
Technical Sentiment Signal: Buy
Current Market Cap: €2.57B
For an in-depth examination of ALM stock, go to TipRanks’ Overview page.